Racura Enters Underwriting Agreement for Options
Key points
- $1.25 Piggyback Options exercised yielding $22.879M
- Agreement with existing shareholder fully underwrites remaining options
- Total raised from Piggyback Options to be $25.2M upon full conversion
Full summary
Racura Oncology Ltd. announced the execution of an underwriting agreement with Dr. AJ Robinson to cover any remaining unexercised $1.25 Piggyback options. This agreement ensures that up to 1,838,524 options will be exercised, raising a maximum of approximately $2.298M. The underwriting is provided by an existing shareholder, with no underwriting fee, commission, or other consideration. The funds will support Racura's clinical programs in AML, lung cancer, and anthracycline cardioprotection, as well as general working capital.
Guidance
Total raised from Piggyback Options to be $25.2M upon full conversion
Outlook
The underwriting agreement aims to ensure continued funding for Racura's clinical development programs, supporting their mission to silence cancer.
Summary generated by a large language model. Please interpret with care.